Subsequent validation in our database confirmed these meta-analysis results, demonstrating that LINC-PINT downregulation is associated with tumor progression in specific cancers, such as prostate cancer, breast cancer, and lung cancer. This evidence concerns the gene LINC-PINT and lung carcinoma.